BioMarin Pharmaceutical has announced its plans to acquire Amicus Therapeutics in a significant all-cash deal valued at $4.8 billion, aimed at enhancing its position in the rare diseases market. The acquisition, which has resulted in a surge in stock prices for both companies, is seen as a strategic move to accelerate revenue growth and strengthen financial outlooks. While some shareholders are investigating the fairness of the sale price, the deal represents a notable consolidation in the rare disease biotech sector.